Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-25-031974
Filing Date
2025-02-21
Accepted
2025-02-21 16:01:21
Documents
13
Period of Report
2025-02-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K/A d862857d8ka.htm   iXBRL 8-K/A 25725
  Complete submission text file 0001193125-25-031974.txt   153524

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nmra-20250213.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nmra-20250213_lab.xml EX-101.LAB 18701
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nmra-20250213_pre.xml EX-101.PRE 11699
15 EXTRACTED XBRL INSTANCE DOCUMENT d862857d8ka_htm.xml XML 4536
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41802 | Film No.: 25651590
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)